← All trials
NCT05269706
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 18, 2022
- Primary completion
- Jun 1, 2023
- Completion date
- Dec 31, 2023
- First posted
- Mar 8, 2022
- Last posted
- Nov 30, 2022
- Enrollment
- 24
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Hurd,Yasmin, Ph.D.Lead sponsor
- Icahn School of Medicine at Mount SinaiOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.